6-116593029-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_015952.4(RWDD1):āc.660C>Gā(p.Asp220Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000187 in 1,612,596 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00015 ( 0 hom., cov: 32)
Exomes š: 0.00019 ( 1 hom. )
Consequence
RWDD1
NM_015952.4 missense
NM_015952.4 missense
Scores
6
13
Clinical Significance
Conservation
PhyloP100: 0.0110
Genes affected
RWDD1 (HGNC:20993): (RWD domain containing 1) Predicted to be involved in several processes, including cellular response to lipid; cytoplasmic translation; and positive regulation of androgen receptor activity. Predicted to be located in cytoplasm. Predicted to be part of polysome. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.26085046).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RWDD1 | NM_015952.4 | c.660C>G | p.Asp220Glu | missense_variant | 7/7 | ENST00000466444.7 | NP_057036.2 | |
RWDD1 | NM_001007464.3 | c.372C>G | p.Asp124Glu | missense_variant | 8/8 | NP_001007465.1 | ||
RWDD1 | NM_016104.4 | c.372C>G | p.Asp124Glu | missense_variant | 9/9 | NP_057188.2 | ||
RWDD1 | XM_047418863.1 | c.372C>G | p.Asp124Glu | missense_variant | 9/9 | XP_047274819.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RWDD1 | ENST00000466444.7 | c.660C>G | p.Asp220Glu | missense_variant | 7/7 | 1 | NM_015952.4 | ENSP00000420357 | P1 | |
RWDD1 | ENST00000487832.6 | c.372C>G | p.Asp124Glu | missense_variant | 8/8 | 1 | ENSP00000428778 |
Frequencies
GnomAD3 genomes AF: 0.000146 AC: 22AN: 150958Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
22
AN:
150958
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000147 AC: 37AN: 251328Hom.: 0 AF XY: 0.000140 AC XY: 19AN XY: 135842
GnomAD3 exomes
AF:
AC:
37
AN:
251328
Hom.:
AF XY:
AC XY:
19
AN XY:
135842
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000191 AC: 279AN: 1461638Hom.: 1 Cov.: 34 AF XY: 0.000177 AC XY: 129AN XY: 727128
GnomAD4 exome
AF:
AC:
279
AN:
1461638
Hom.:
Cov.:
34
AF XY:
AC XY:
129
AN XY:
727128
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000146 AC: 22AN: 150958Hom.: 0 Cov.: 32 AF XY: 0.000122 AC XY: 9AN XY: 73566
GnomAD4 genome
AF:
AC:
22
AN:
150958
Hom.:
Cov.:
32
AF XY:
AC XY:
9
AN XY:
73566
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
5
ExAC
AF:
AC:
11
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 29, 2022 | The c.660C>G (p.D220E) alteration is located in exon 7 (coding exon 7) of the RWDD1 gene. This alteration results from a C to G substitution at nucleotide position 660, causing the aspartic acid (D) at amino acid position 220 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Benign
Sift
Benign
D;T
Sift4G
Benign
T;T
Polyphen
D;.
Vest4
MutPred
Gain of helix (P = 0.0325);.;
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at